Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

Presentation EuroPCR 2019

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Presenter: Clemens von Birgelen

May 21, 2019

Presentation TCT 2018

BIONYX: Summary and Clinical Implications

Presenter: Sripal Bangalore, Lawrence A. Garcia, Clemens von Birgelen

September 22, 2018

Presentation TCT 2018

BIONYX: A Randomized Trial Evaluating a Thin Composite Wire Strut Durable Polymer-Based DES Compared with an Ultra-Thin Strut Bioresorbable Polymer-Based DES in an All-Comers Patient Population

Presenter: Gregg W. Stone, Clemens von Birgelen

September 22, 2018

Presentation TCT 2018

Ultra-Thin Strut DES: A Meaningful Advance?

Presenter: Renu Virmani, Clemens von Birgelen, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Presenter: Renu Virmani, Clemens von Birgelen, David E. Kandzari

September 22, 2018

Presentation TCT 2018

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Presenter: Renu Virmani, Clemens von Birgelen, Michael Joner

September 22, 2018

Presentation TCT 2017

Should Pre-Diabetes Affect Revascularization Decisions?

Presenter: David J. Maron, Alan C. Yeung, Clemens von Birgelen

November 01, 2017

Presentation TCT 2017

The Orsiro Sirolimus-eluting Stent: Outcomes From the BIOFLOW and BIORESORT Trials

Presenter: Ioannis Iakovou, Gert Richardt, Clemens von Birgelen

October 30, 2017

Presentation TCT 2017

Are All Contemporary DES Comparable? Lessons From the TWENTE Trials

Presenter: Giulio G. Stefanini, Stephan Windecker, Clemens von Birgelen

October 30, 2017

Presentation EuroPCR 2017

BIO-RESORT Silent Diabetes

Presenter: Clemens von Birgelen

May 19, 2017

Presentation TCT 2016

TCT 313: Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 312: Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An Analysis of the BASKET-PROVE I and II trials.

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 401: Bioresorbable Scaffolds And Thrombosis: Insights From The GHOST-EU (Gauging coronary Healing with Bioresorbable Scaffolding Platforms in Europe) Registry

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 402: Relationship Between Bioresorbable Scaffold Sizing and Scaffold Thrombosis: A Pooled Analysis of ABSORB Trials

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2015

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

Presenter: Bernard J. Gersh, Thomas F. Luscher, Clemens von Birgelen

October 14, 2015

Presentation TCT 2015

Device and Clinical Program Highlights: DESyne BD

Presenter: Pieter C. Smits, Philip M. Urban, Tim A. Fischell, Elvin Kedhi, Karel T. Koch, Marco A. Perin, Ashok Seth, Clemens von Birgelen

October 12, 2015

Presentation TCT 2014

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Presenter: Clemens von Birgelen

September 16, 2014

Presentation

Third-Gen ZES and EES in All-Comers Patients Requiring PCI: DUTCH PEERS Noninferiority Trial

Presenter: Clemens von Birgelen

February 09, 2014

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Advertisement

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

BIONYX: Summary and Clinical Implications

BIONYX: A Randomized Trial Evaluating a Thin Composite Wire Strut Durable Polymer-Based DES Compared with an Ultra-Thin Strut Bioresorbable Polymer-Based DES in an All-Comers Patient Population

Ultra-Thin Strut DES: A Meaningful Advance?

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Should Pre-Diabetes Affect Revascularization Decisions?

The Orsiro Sirolimus-eluting Stent: Outcomes From the BIOFLOW and BIORESORT Trials

Are All Contemporary DES Comparable? Lessons From the TWENTE Trials

BIO-RESORT Silent Diabetes

TCT 313: Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials

TCT 312: Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An Analysis of the BASKET-PROVE I and II trials.

TCT 401: Bioresorbable Scaffolds And Thrombosis: Insights From The GHOST-EU (Gauging coronary Healing with Bioresorbable Scaffolding Platforms in Europe) Registry

TCT 402: Relationship Between Bioresorbable Scaffold Sizing and Scaffold Thrombosis: A Pooled Analysis of ABSORB Trials

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

Device and Clinical Program Highlights: DESyne BD

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Third-Gen ZES and EES in All-Comers Patients Requiring PCI: DUTCH PEERS Noninferiority Trial

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content